Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Family Medicine | Gynecology | Infections | AIDS | Internal Medicine | Journal

Back to Journal Articles

Minimum Threshold Suggested for HIV Antiretroviral Therapy

Last Updated: April 09, 2009.

 

Analysis of 18 studies shows benefit of starting therapy when CD4 counts are 350 or below

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
In AIDS-free HIV-infected patients, a CD4 cell count of 350 should be the minimum threshold for initiation of antiretroviral therapy, according to a study published online April 9 in The Lancet.

THURSDAY, April 9 (HealthDay News) -- In AIDS-free HIV-infected patients, a CD4 cell count of 350 should be the minimum threshold for initiation of antiretroviral therapy, according to a study published online April 9 in The Lancet.

Jonathan Sterne, Ph.D., of the University of Bristol, U.K., and colleagues from the When To Start Consortium analyzed data from 18 cohort studies of 21,247 patients who were followed up before the introduction of combination therapy and 24,444 patients who were followed up from the start of treatment.

The researchers found that the rates of AIDS and death were higher in patients starting combination therapy with a CD4 cell count of 251 to 350 than in those starting therapy with CD4 cell counts of 351 to 450 (hazard ratio, 1.28). They also found the rates of overall mortality were higher in patients with CD4 cell counts of 251 to 350 who deferred treatment (hazard ratio, 1.13).

"Thus, our findings should help to guide physicians and patients in deciding when to start antiretroviral treatment," the authors write. "The evolution of guidelines has been compared to the swings of a pendulum, from initial enthusiasm for early treatment, through to caution because of concern about toxic effects and the risk of resistance and loss of treatment options, to more recent calls for earlier treatment."

A variety of pharmaceutical industry financial disclosures were made by the authors.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Sorafenib May Improve Portal Hypertension Next: Lumbar Arthrodesis Good Option for Older Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.